Visus Therapeutics to Present at the Baird 2022 Global Healthcare Conference

SEATTLE, Wash. – September 7, 2022 – Visus Therapeutics, Inc. (“Visus”), a clinical stage biopharmaceutical company focused on treating complex and multifactorial conditions from the front to the back of the eye, today announced that Ben Bergo, co-founder and chief executive officer, will present at the Baird 2022 Global Healthcare Conference on September 13th, 2022, at the InterContinental New York Barclay hotel.

The presentation is scheduled for 12:50 PM Eastern Time on Tuesday, September 13th. Mr. Bergo will also be available for one-on-one investor meetings on Tuesday, September 13th.

The company presentation will be available on Visus’ website at https://www.visustx.com/news.

About Visus Therapeutics

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical stage biopharmaceutical company focused on treating complex and multifactorial conditions from the front to the back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus Therapeutics is focused on advancing its pipeline of early-stage ophthalmic drug candidates with applications in corneal wound healing, glaucoma and age-related macular degeneration. For more information, visit: www.visustx.com and follow us on LinkedIn, Twitter, and Instagram.

Investor Relations Contacts:

LaVoieHealthScience
James Heins
jheins@lavoiehealthscience.com
(646) 491-7042

Paul Sagan
Psagan@lavoiehealthscience.com
(617) 865-0041

###